Livzon Pharmaceutical Group, Inc. (01513.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 20.74

From 52W high−45.04%

Volume2.74M

Market capHKD 18.11B

P/E (TTM)9.2x

P/S (TTM)1.4x

Div yield8.05%

Key dataSep 18, 2026

Open

HKD 20.74

From 52W high

−45.04%

Volume

2.74M

Market cap

HKD 18.11B

ValuationView details →

P/E (Fwd)

17.1x

EV/EBITDA

4.7x

P/E (TTM)

9.2x

RSI (14)

32.2

MomentumView details →

1D Return

−1.16%

YTD Return

−28.47%

ValuationView details →

P/E (Fwd)

17.1x

P/E (TTM)

9.2x

EV/EBITDA

4.7x

EV/Sales

1.2x

P/S (TTM)

1.4x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

63.33%

Net Margin

15.60%

EBITDA Margin

25.25%

ROE (TTM)

12.49%

ROA (TTM)

7.07%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

−9.38%

EPS YoY

−21.25%

FCF YoY

+73.66%

Revenue CAGR 3Y

−1.63%

EPS CAGR 3Y

+3.63%

EBITDA YoY

−12.82%

MomentumView details →

1D Return

−1.16%

YTD Return

−28.47%

1Y Return

−42.50%

RSI (14)

32.2

vs 50D SMA

−14.29%

vs 200D SMA

−24.71%

Capital & dividendView details →

Debt/Equity

0.32x

Current Ratio

1.55x

Quick Ratio

1.34x

Div Yield

8.05%

Div Rate

HKD 1.64

Div Growth 1Y

+37.06%

EarningsView details →

EPS (Actual)

HKD 0.46

EPS Surprise

−37.51%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.60

Avg Surprise (4Q)

−37.51%

Rev Surprise

−27.92%

Financials snapshotView financials →

Revenue (TTM)

10.70B

Net Income (TTM)

1.67B

Op. CF (TTM)

3.30B

Next earningsOct 27, 2026 →

Latest newsMore news →

Livzon Pharmaceutical Group announced a special interim dividend of RMB 1.02 per share, totaling over RMB 905 million, approved by its board on September 8, 2026.12d ago

Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.24d ago

Similar companies

HUTCHMED (China) Limited00013.HK Grand Pharmaceutical Group Limited00512.HK 健康元600380.SH Viatris Inc.VTRS 皓元医药688131.SH 华润双鹤600062.SH Find similar companies →

Latest newsMore news →

Livzon Pharmaceutical Group announced a special interim dividend of RMB 1.02 per share, totaling over RMB 905 million, approved by its board on September 8, 2026.12d ago Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.24d ago